source
- Novo Nordisk licenses weekly oral obesity peptide from Hengrui in up to $2.6 billion dealNovo Nordisk has signed a licensing agreement with China's Hengrui Pharma for a once‑weekly oral peptide, HRS‑1596, aimed at obesity and other metabolic conditions. Novo will pay $300 million upfr…
- SK pharmteco hosts webinar on overcoming ADC linker-payload manufacturing challengesSK pharmteco’s European and North American teams presented a webinar that explored the full lifecycle of antibody‑drug conjugate (ADC) linker‑payload development, from facility design to final prod…